Pacira Pharma (PCRX) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Wedbush Raises Price Target on Pacira Pharma (PCRX) Following 3Q Beat
October 27, 2015 5:20 PM EDTWedbush reiterated an Outperform rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target to $113.00 (from $106.00), following the company's 3Q earnings results. Total revenues of $62.2MM beat consensus of $60.4MM and diluted GAAP EPS of $0.08 also beat consensus of $0.02.
Analyst Liana Moussatos... More



